May selective serotonin reuptake inhibitors (SSRIs) provide some benefit for the treatment of schizophrenia?

Massimiliano Buoli, Marta Serati, Valentina Ciappolino, A. Carlo Altamura

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

ABSTRACT: Introduction: The treatment of some psychopathological dimensions of schizophrenia (e.g. negative and depressive symptoms) is still challenging for the modest efficacy of atypical antipsychotics. Among pharmacological alternatives, augmentative Selective Serotonin Reuptake Inhibitors (SSRIs) to antipsychotics are frequently prescribed in clinical practice to improve negative/depressive symptoms of schizophrenia patients; however, the data about the efficacy of these molecules on negative, depressive and obsessive-compulsive symptoms of schizophrenia are contrasting. Areas Covered: Research using the main database sources has been conducted to obtain an overview of the use and efficacy of SSRIs in schizophrenia. Expert Opinion: Data are too scanty to draw definitive recommendations. In a preliminary way, it can be said that available data do not show effectiveness of SSRIs on depressive symptoms of schizophrenia. Regarding negative symptoms, studies are contrasting, but paroxetine appears to be the most effective compound among SSRIs. Despite limited data, SSRIs appear to be useful for the treatment of obsessive-compulsive symptoms of schizophrenia, particularly fluvoxamine. Close clinical and pharmacological monitoring is needed in case of concomitant administration of antipsychotics and antidepressants for potential serious side effects and influence on plasma drug dosages

Original languageEnglish
Pages (from-to)1375-1385
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume17
Issue number10
DOIs
Publication statusPublished - Jul 2 2016

Fingerprint

Serotonin Uptake Inhibitors
Schizophrenia
Antipsychotic Agents
Depression
Therapeutics
Pharmacology
Fluvoxamine
Paroxetine
Expert Testimony
Antidepressive Agents
Databases
Research
Pharmaceutical Preparations

Keywords

  • depression
  • negative symptoms
  • obsessive-compulsive symptoms
  • schizophrenia
  • Selective Serotonin Reuptake Inhibitors (SSRIs)

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

May selective serotonin reuptake inhibitors (SSRIs) provide some benefit for the treatment of schizophrenia? / Buoli, Massimiliano; Serati, Marta; Ciappolino, Valentina; Altamura, A. Carlo.

In: Expert Opinion on Pharmacotherapy, Vol. 17, No. 10, 02.07.2016, p. 1375-1385.

Research output: Contribution to journalReview article

@article{96cfd7e7ae944ef9b34a7d1fde52a85a,
title = "May selective serotonin reuptake inhibitors (SSRIs) provide some benefit for the treatment of schizophrenia?",
abstract = "ABSTRACT: Introduction: The treatment of some psychopathological dimensions of schizophrenia (e.g. negative and depressive symptoms) is still challenging for the modest efficacy of atypical antipsychotics. Among pharmacological alternatives, augmentative Selective Serotonin Reuptake Inhibitors (SSRIs) to antipsychotics are frequently prescribed in clinical practice to improve negative/depressive symptoms of schizophrenia patients; however, the data about the efficacy of these molecules on negative, depressive and obsessive-compulsive symptoms of schizophrenia are contrasting. Areas Covered: Research using the main database sources has been conducted to obtain an overview of the use and efficacy of SSRIs in schizophrenia. Expert Opinion: Data are too scanty to draw definitive recommendations. In a preliminary way, it can be said that available data do not show effectiveness of SSRIs on depressive symptoms of schizophrenia. Regarding negative symptoms, studies are contrasting, but paroxetine appears to be the most effective compound among SSRIs. Despite limited data, SSRIs appear to be useful for the treatment of obsessive-compulsive symptoms of schizophrenia, particularly fluvoxamine. Close clinical and pharmacological monitoring is needed in case of concomitant administration of antipsychotics and antidepressants for potential serious side effects and influence on plasma drug dosages",
keywords = "depression, negative symptoms, obsessive-compulsive symptoms, schizophrenia, Selective Serotonin Reuptake Inhibitors (SSRIs)",
author = "Massimiliano Buoli and Marta Serati and Valentina Ciappolino and Altamura, {A. Carlo}",
year = "2016",
month = "7",
day = "2",
doi = "10.1080/14656566.2016.1186646",
language = "English",
volume = "17",
pages = "1375--1385",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - May selective serotonin reuptake inhibitors (SSRIs) provide some benefit for the treatment of schizophrenia?

AU - Buoli, Massimiliano

AU - Serati, Marta

AU - Ciappolino, Valentina

AU - Altamura, A. Carlo

PY - 2016/7/2

Y1 - 2016/7/2

N2 - ABSTRACT: Introduction: The treatment of some psychopathological dimensions of schizophrenia (e.g. negative and depressive symptoms) is still challenging for the modest efficacy of atypical antipsychotics. Among pharmacological alternatives, augmentative Selective Serotonin Reuptake Inhibitors (SSRIs) to antipsychotics are frequently prescribed in clinical practice to improve negative/depressive symptoms of schizophrenia patients; however, the data about the efficacy of these molecules on negative, depressive and obsessive-compulsive symptoms of schizophrenia are contrasting. Areas Covered: Research using the main database sources has been conducted to obtain an overview of the use and efficacy of SSRIs in schizophrenia. Expert Opinion: Data are too scanty to draw definitive recommendations. In a preliminary way, it can be said that available data do not show effectiveness of SSRIs on depressive symptoms of schizophrenia. Regarding negative symptoms, studies are contrasting, but paroxetine appears to be the most effective compound among SSRIs. Despite limited data, SSRIs appear to be useful for the treatment of obsessive-compulsive symptoms of schizophrenia, particularly fluvoxamine. Close clinical and pharmacological monitoring is needed in case of concomitant administration of antipsychotics and antidepressants for potential serious side effects and influence on plasma drug dosages

AB - ABSTRACT: Introduction: The treatment of some psychopathological dimensions of schizophrenia (e.g. negative and depressive symptoms) is still challenging for the modest efficacy of atypical antipsychotics. Among pharmacological alternatives, augmentative Selective Serotonin Reuptake Inhibitors (SSRIs) to antipsychotics are frequently prescribed in clinical practice to improve negative/depressive symptoms of schizophrenia patients; however, the data about the efficacy of these molecules on negative, depressive and obsessive-compulsive symptoms of schizophrenia are contrasting. Areas Covered: Research using the main database sources has been conducted to obtain an overview of the use and efficacy of SSRIs in schizophrenia. Expert Opinion: Data are too scanty to draw definitive recommendations. In a preliminary way, it can be said that available data do not show effectiveness of SSRIs on depressive symptoms of schizophrenia. Regarding negative symptoms, studies are contrasting, but paroxetine appears to be the most effective compound among SSRIs. Despite limited data, SSRIs appear to be useful for the treatment of obsessive-compulsive symptoms of schizophrenia, particularly fluvoxamine. Close clinical and pharmacological monitoring is needed in case of concomitant administration of antipsychotics and antidepressants for potential serious side effects and influence on plasma drug dosages

KW - depression

KW - negative symptoms

KW - obsessive-compulsive symptoms

KW - schizophrenia

KW - Selective Serotonin Reuptake Inhibitors (SSRIs)

UR - http://www.scopus.com/inward/record.url?scp=84975217874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975217874&partnerID=8YFLogxK

U2 - 10.1080/14656566.2016.1186646

DO - 10.1080/14656566.2016.1186646

M3 - Review article

VL - 17

SP - 1375

EP - 1385

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -